Interní Med. 2016; 18(1): 19-24 [Dermatol. praxi. 2015;9(3):99-103]
Ustekinumab is a fully human IgG1κ monoclonal antibody that inhibits interleukin 12 and 23 functions by binding to their p40 subunit. Ustekinumab is used in treating moderate and severe form of dermal psoriasis; however, a number of clinical studies have shown its effect on extradermal manifestations, particularly on the musculoskeletal system. PSUMMIT-1 and -2 clinical studies in patients with psoriatic arthritis have demonstrated good properties of ustekinumab for inducing a rapid therapeutic response with a good safety profile, and allowed registration for this indication as well.
Published: February 1, 2016 Show citation